Want to see ENTX full AI Analyst Report?
ENTX Stock Chart & Stats
$1.28
-$0.11(-4.20%)
At close: 4:00 PM EST
$1.28
-$0.11(-4.20%)
Day’s Range― - ―
52-Week Range$0.91 - $3.22
Previous CloseN/A
Volume29.71K
Average Volume (3M)123.78K
Market Cap
$87.24M
Enterprise Value$55.46M
Total Cash (Recent Filing)$4.14M
Total Debt (Recent Filing)$448.00K
Price to Earnings (P/E)―
Beta0.38
Next Earnings
Aug 07, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding49,290,234
10 Day Avg. Volume240,874
30 Day Avg. Volume123,776
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)6.84
Price to Sales (P/S)2133.59
P/FCF Ratio-11.98
Enterprise Value/Market Cap0.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.70K
Enterprise Value/Ebitda-4.49
Forecast
1Y Price Target
$9.00Price Target Upside603.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.42
Revenue Forecast (FY)$54.58M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetVery low debt relative to equity materially reduces bankruptcy and refinancing risk for a cash-burning clinical-stage biotech. This structural strength preserves financial flexibility to fund trials or negotiate partnerships without immediate pressure to service debt, supporting program continuity.
Recent Financing Increased RunwayThe $10M private placement meaningfully bolstered liquidity, explicitly extending expected runway into Q1 2027. Durable capital infusion reduces near-term refinancing risk, enables initiation of the planned Phase 3 for EB613, and provides time to achieve de-risking milestones or secure partners.
Advancing Pipeline & PartnershipsRegulatory and clinical progress (Phase 3 protocol submission and bridging data) plus a strengthened OPKO partnership reflect durable program advancement and shared development risk. These structural developments increase the probability of registrational success and potential non-dilutive partner funding.
Bears Say
No Commercial RevenueWith no recurring commercial revenue, Entera depends on external financing, milestones, or partnerships to fund operations. This structural lack of cash flow lengthens the time to self-sufficiency and elevates execution risk relative to companies with product-derived income streams.
High Cash Burn / Negative Cash GenerationSubstantially negative operating and free cash flow indicates the company is burning cash at a pace that will require repeated financing to sustain multi-year clinical programs. This persistent cash consumption increases dilution risk and constrains the ability to run multiple registrational studies simultaneously.
Equity Erosion & Negative ROEDeclining shareholders' equity and materially negative ROE reflect ongoing capital erosion from losses. Over time this reduces the equity buffer available to absorb setbacks and increases the likelihood of dilutive financings, which can compress long-term shareholder value if milestones are delayed.
Entera Bio News
ENTX FAQ
What was Entera Bio Ltd’s price range in the past 12 months?
Entera Bio Ltd lowest stock price was $0.91 and its highest was $3.22 in the past 12 months.
What is Entera Bio Ltd’s market cap?
Entera Bio Ltd’s market cap is $87.24M.
When is Entera Bio Ltd’s upcoming earnings report date?
Entera Bio Ltd’s upcoming earnings report date is Aug 07, 2026 which is in 37 days.
How were Entera Bio Ltd’s earnings last quarter?
Entera Bio Ltd released its earnings results on May 08, 2026. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.08 by $0.01.
Is Entera Bio Ltd overvalued?
According to Wall Street analysts Entera Bio Ltd’s price is currently Undervalued.
Does Entera Bio Ltd pay dividends?
Entera Bio Ltd does not currently pay dividends.
What is Entera Bio Ltd’s EPS estimate?
Entera Bio Ltd’s EPS estimate is -0.08.
How many shares outstanding does Entera Bio Ltd have?
Entera Bio Ltd has 49,290,234 shares outstanding.
What happened to Entera Bio Ltd’s price movement after its last earnings report?
Entera Bio Ltd reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.08. Following the earnings report the stock price went down -10%.
Which hedge fund is a major shareholder of Entera Bio Ltd?
Currently, no hedge funds are holding shares in ENTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Entera Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (603.13% Upside)
$9.00 (603.13% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.3%
Last 30 Days ▲ 16.3%
Last 30 Days ▲ 16.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.41%
12-Months-Change
Fundamentals
Return on Equity
-87.97%
Trailing 12-Months
Asset Growth
-39.22%
Trailing 12-Months
Company Description
Entera Bio Ltd
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
ENTX Stock 12 Month Forecast
Average Price Target
$9.00
▲(603.13% Upside)
Technical Analysis
Ownership Overview
3.47% Insiders
0.04% Mutual Funds
13.13% Other Institutional Investors
83.36% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---